Skip to content
Peptide research

Sigumir

Also known as Cartilage Bioregulator
Category
Bioregulators
Administration routes
Oral
Regulatory status
Not FDA-approved

A bioregulator peptide complex from cartilage and bone tissue, marketed for joint pain and cartilage health in osteoarthritis. The case is thin: pain relief has only low-confidence support, and mobility claims have limited observational support, while the proposed metabolic effects remain unestablished. The main risk is inconsistent manufacturing quality, with a low chance of allergic reaction to its bovine source. Not an approved drug in the US; it is marketed as a dietary supplement in Russia.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Sigumir is a natural peptide bioregulator containing a complex of low-molecular-weight peptides (under 5,000 Da) extracted from the cartilaginous tissue of young calves. Developed by Professor Vladimir Khavinson, it belongs to the Cytomaxes class and targets cartilage and bone tissue, where it is designed to improve trophism (nutrition) of cartilaginous tissue cells and regulate metabolic processes, reducing the risk of joint and spine diseases.

Clinical studies conducted at the St. Petersburg Institute of Bioregulation and Gerontology tested Sigumir in patients with osteoarthritis of knee joints, spinal osteochondrosis, and osteoporosis. The study enrolled 33 patients (ages 45-78) with disease durations of 5-20 years. Results showed reduction of pain syndrome, improved joint mobility, and enhanced cartilage tissue function compared to standard treatment alone. An additional PubMed-indexed study (PMID 22708467) evaluated Sigumir in 62 elderly patients with temporomandibular joint disorders, showing improved pain relief, increased mouth opening, and better chewing function.

Sigumir is manufactured in capsule form and is marketed as a dietary supplement in Russia.

How it works in the body

A bioregulator peptide complex derived from cartilage and bone tissue. It interacts with DNA in chondrocytes to upregulate genes involved in proteoglycan synthesis, collagen production, and cartilage matrix maintenance, supporting joint integrity and slowing age-related cartilage degradation.

Research overview

Sigumir has better documented clinical evidence than many Khavinson bioregulators, with a formal clinical study report published by the St. Petersburg Institute and a PubMed-indexed study. The Institute's clinical study tested Sigumir in 33 patients with osteoarthritis, osteochondrosis, and osteoporosis against 31 matched controls receiving standard treatment alone. The PMID 22708467 study evaluated Sigumir in 62 elderly patients with temporomandibular joint pathology, demonstrating improvements in pain, joint function, and reduced treatment duration when Sigumir was added to standard therapy. A follow-up study (PMID 36617325) on bioregulation therapy for age-related TMJ osteoarthropathy also references Sigumir. While these studies are more rigorous than typical bioregulator reports, they still lack Western-standard blinding and randomization.

Who researches Sigumir?

Commonly researched by

  • People researching inflammation management

    Studied for anti-inflammatory effects across various conditions.

  • People researching reduction of pain in osteoarthritis and osteochondrosis

    One of the primary studied benefits of Sigumir.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(2)

Rated by level of concern

  • Allergic reaction to bovine cartilage-derived peptides

    Low

    Product composition per PMID 37782637 ('polypeptide complex of cartilage and bone tissues of young animals'); no Sigumir adverse-event literature found in PubMed or FDA sources

  • Lack of independent quality control

    Moderate

    Absence of FDA approval or ClinicalTrials.gov records for Sigumir; no independent analytical characterization located in PubMed

Interaction summary(6)

Rated by direction with this peptide

  • Bovine/beef protein allergy, including alpha-gal syndrome

    CautionLow

    Not a drug interaction but a contraindication: the product is an animal cartilage/bone extract, so people with known beef or bovine-protein allergy (or alpha-gal sensitization) are the one group with a concrete, if undocumented, reason to avoid it. Severity kept Low because no reaction to Sigumir has ever been reported, though hypersensitivity to animal-protein products can in principle be severe.

    Mechanistic — product source described in PMID 37782637; no reported cases

  • Intra-articular or systemic corticosteroids

    CautionTheoretical

    Corticosteroids are well documented to suppress chondrocyte proteoglycan and collagen synthesis, which would work directly against Sigumir's proposed matrix-supporting mechanism. This is an efficacy-antagonism concern, not a safety hazard, and no interaction study exists.

    Mechanistic — corticosteroid chondrotoxicity is established in the general literature; no Sigumir-specific data

  • NSAIDs (ibuprofen, diclofenac, celecoxib)

    NeutralTheoretical

    Pharmacotherapy was part of the background regimen in the Russian geriatric TMJ protocol in which Sigumir was used, with no reported adverse interaction; concurrent symptomatic drug therapy also makes any Sigumir-specific effect impossible to isolate. Note that the source describes 'pharmacotherapy' generally rather than naming individual NSAIDs.

    PMID 22708467 (Sigumir co-administered within multimodal therapy including pharmacotherapy)

  • Glucosamine and chondroitin sulfate

    NeutralTheoretical

    No study supports an additive benefit, and Sigumir's own matrix-supporting mechanism is itself unestablished. Combined use has no known safety concern and no published combination data.

    No data; mechanistic speculation only

  • Other Khavinson-type peptide bioregulators (e.g. bone, vascular, thymic preparations)

    NeutralTheoretical

    These products are routinely combined in the Russian bioregulator literature without reported interaction, but the combinations have never been formally studied for safety or additive effect.

    PMID 32362097 (bioregulatory therapy protocols); no interaction data

  • Immunosuppressants and biologic DMARDs (methotrexate, TNF inhibitors)

    CautionTheoretical

    An unstandardized animal-tissue extract of unverified sterility and antigenic content is a poor pairing with pharmacologic immunosuppression; the concern is product-quality-driven, not a pharmacokinetic interaction, and no case has been reported.

    Mechanistic — derives from the documented absence of independent quality control, not from any reported case

Known risks(2)

  • Allergic reaction to bovine cartilage-derived peptides

    Low

    Theoretical risk; no serious adverse events reported in clinical studies.

  • Lack of independent quality control

    Moderate

    Product not subject to FDA/EMA oversight; quality and consistency may vary.

Drug interactions(2)

  • NSAIDs (ibuprofen, diclofenac, etc.)

    No known interaction; commonly used concurrently in Russian clinical practice

  • Corticosteroids (intra-articular or systemic)

    No documented interaction; monitor as with any new supplement

Research & benefits

Evidence base

Evidence Level
Limited Evidence (better than most bioregulators)
Total Studies
5

Sigumir has two PubMed-indexed clinical studies and a detailed Institute clinical report. The main study tested 33 patients with musculoskeletal conditions against 31 controls over 30-45 day courses. The TMJ study (PMID 22708467) was larger with 62 patients and showed significant improvements. While these represent better evidence than most bioregulators, they still lack double-blind randomization and have not been replicated outside Russia.

Researched for(4)

Rated by confidence in the evidence

  • Reduction of pain in osteoarthritis and osteochondrosis

    Low

    Animal osteoarthritis models show efficacy; human evidence limited to small uncontrolled observations.

    PMID 37782637 (Adv Gerontol 2023;36(3):313-323, review describing Sigumir and animal-model OA efficacy); no ClinicalTrials.gov records for Sigumir

  • Improved joint mobility and function

    Speculative

    Small reports describe mobility improvements during combined treatment; an isolated Sigumir effect remains unestablished.

    PMID 22708467 (Adv Gerontol 2012;25(1):181-6 — 62 elderly TMJ patients, Sigumir within combined treatment)

  • Support for cartilage tissue metabolism and trophism

    Speculative

    Mechanism-based only; supporting studies involve other peptides or bone density, not this peptide.

    PMID 37176122 (Int J Mol Sci 2023, review of peptide chondrogenic regulation, not Sigumir-specific); PMID 18306703 (Adv Gerontol 2007, aging/ovariectomized rats, bone density endpoint)

  • Improved temporomandibular joint function in elderly

    Speculative

    Single 62-patient uncontrolled study, part of a combined treatment; no independent replication.

    PMID 22708467; PMID 32362097 (Adv Gerontol 2020;33(1):137-152, review of bioregulatory therapy in dental disease naming sigumir)

Benefits(4)

  • Reduction of pain in osteoarthritis and osteochondrosis

    Khavinson Institute clinical study (33 patients); PMID 22708467 (62 patients)

  • Improved joint mobility and function

    Khavinson Institute clinical study

  • Support for cartilage tissue metabolism and trophism

    Preclinical data; Khavinson Institute tissue-specific peptide research

  • Improved temporomandibular joint function in elderly

    PMID 22708467; PMID 36617325

Key studies(2)

  1. Iordanishvili AK, Samsonov VV, Soldatova LN, Polens AA, Ryzhak GA

    Advances in Gerontology

    2012

    Sigumir in complex therapy for elderly TMJ patients improved pain relief, mouth opening, chewing function, reduced treatment duration, and prevented relapses throughout the observation period.

  2. Clinical study of peptide bioregulator Sigumir (Khavinson Institute Report)

    Open-label clinical studyn=33 treatment + n=31 control30-45 days

    Khavinson VKh et al.

    St. Petersburg Institute of Bioregulation and Gerontology (internal report)

    2011

    Patients with osteoarthritis, osteochondrosis, and osteoporosis showed reduced pain, improved joint mobility, and better cartilage function vs. standard therapy alone.

Regulation & availability

Why researchers look at it

Sigumir delivers cartilage-specific peptides aimed at restoring joint tissue metabolism and reducing age-related degeneration. It has some of the better clinical documentation among Khavinson bioregulators, including PubMed-indexed studies in joint pathology.

Estimated cost
$30-60/mo (capsules)
FDA status
Not FDA-approved; not reviewed by FDA; sold as dietary supplement internationally
WADA status
Not individually named on the WADA 2026 Prohibited List. S0 can prohibit unapproved pharmacological substances at all times; supplement registration does not establish therapeutic approval. Product-specific anti-doping status requires confirmation.
Prescribability
Available in Russia as dietary supplement; not approved in USA/EU
Availability
Manufactured by GARMONIA Ltd. (St. Petersburg). Not available through conventional pharmacies in USA/EU.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(3)

  1. 2000s
    Clinical study conducted at St. Petersburg Institute (Nov 2005 - Feb 2006)
  2. 2011
    Available institute clinical report dated 2011 describes the study conducted during 2005–2006.
  3. 2012
    PubMed-indexed TMJ study published (PMID 22708467)

Sources & FAQs

Research sources(3)

Frequently asked questions(3)

What conditions is Sigumir used for?

Sigumir is used as a dietary supplement for joint and bone conditions including osteoarthritis, osteochondrosis, osteoporosis, and age-related cartilage degeneration. It has also been studied for temporomandibular joint disorders.

How long does it take for Sigumir to show effects?

In clinical studies, improvements in pain and function were observed during treatment. Effects are reported to persist for several months after treatment ends.

Can Sigumir replace glucosamine or chondroitin?

Sigumir works by a different mechanism than glucosamine/chondroitin. Rather than providing structural building blocks, it is intended to regulate cellular metabolism in cartilage tissue through peptide signaling. Some practitioners use it alongside traditional joint supplements.